Polymorphism, a condition in which an active ingredient can exist in more than one crystal form (each with a potentially different impact), has long bedeviled drug makers and QA/QC departments. Researchers in the U.K. (at the University of Warwick and AstraZeneca) have discovered a new way of using NMR that can detect polymorphism in crystalline pharmaceuticals, even those in tablet form, more effectively than traditional methods. Their method (another unfortunate pharma acronym---paging Pharma Giles!): high-resolution two-dimensional 1H CRAMPS solid-state NMR, which reportedly yielded a spectrum for a tablet formulation in less than two hours (roughly the time required for the traditional 13C CP MAS one dimensional spectrum). For more, read on.
AMS
Latest from Home
Latest from Home